Cargando…

Cytochrome P450 eicosanoids in hypertension and renal disease

PURPOSE OF REVIEW: Cytochrome (CYP) P450 metabolites of arachidonic acid, 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs) contribute to the regulation of renal tubular and vascular function. This review highlights the results of the recent genetic studies in humans and...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Fan, Muroya, Yoshikazu, Roman, Richard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260681/
https://www.ncbi.nlm.nih.gov/pubmed/25427230
http://dx.doi.org/10.1097/MNH.0000000000000088
_version_ 1782348207222685696
author Fan, Fan
Muroya, Yoshikazu
Roman, Richard J.
author_facet Fan, Fan
Muroya, Yoshikazu
Roman, Richard J.
author_sort Fan, Fan
collection PubMed
description PURPOSE OF REVIEW: Cytochrome (CYP) P450 metabolites of arachidonic acid, 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs) contribute to the regulation of renal tubular and vascular function. This review highlights the results of the recent genetic studies in humans and rodent models, indicating that these eicosanoids participate in the control of blood pressure (BP), chronic kidney disease (CKD), renal ischemia–reperfusion injury (IRI) and polycystic kidney disease (PKD). RECENT FINDINGS: Endogenous 20-HETE has been reported to play an essential role in the myogenic and tubuloglomerular feedback responses in the afferent arteriole, and a deficiency of 20-HETE contributes to the development of hypertension and renal injury in Dahl S rats. Mutations in CYP4A11 and CYP4F2 have been linked to elevated BP in humans. EETs have been shown to regulate epithelial sodium channel in the collecting duct, lower BP and have renoprotective properties. 20-HETE also opposes the development of CKD and IRI, and may play a role in PKD. SUMMARY: These studies indicate that CYP P450 metabolites of arachidonic acid play an important role in the control of BP, CKD, AKI and PKD. Drugs targeting these pathways could be useful in the treatment of IRI and CKD.
format Online
Article
Text
id pubmed-4260681
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-42606812014-12-09 Cytochrome P450 eicosanoids in hypertension and renal disease Fan, Fan Muroya, Yoshikazu Roman, Richard J. Curr Opin Nephrol Hypertens CIRCULATION AND HEMODYNAMICS: Edited by Matthew R. Weir and Roland C. Blantz PURPOSE OF REVIEW: Cytochrome (CYP) P450 metabolites of arachidonic acid, 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs) contribute to the regulation of renal tubular and vascular function. This review highlights the results of the recent genetic studies in humans and rodent models, indicating that these eicosanoids participate in the control of blood pressure (BP), chronic kidney disease (CKD), renal ischemia–reperfusion injury (IRI) and polycystic kidney disease (PKD). RECENT FINDINGS: Endogenous 20-HETE has been reported to play an essential role in the myogenic and tubuloglomerular feedback responses in the afferent arteriole, and a deficiency of 20-HETE contributes to the development of hypertension and renal injury in Dahl S rats. Mutations in CYP4A11 and CYP4F2 have been linked to elevated BP in humans. EETs have been shown to regulate epithelial sodium channel in the collecting duct, lower BP and have renoprotective properties. 20-HETE also opposes the development of CKD and IRI, and may play a role in PKD. SUMMARY: These studies indicate that CYP P450 metabolites of arachidonic acid play an important role in the control of BP, CKD, AKI and PKD. Drugs targeting these pathways could be useful in the treatment of IRI and CKD. Lippincott Williams & Wilkins 2015-01 2014-12-04 /pmc/articles/PMC4260681/ /pubmed/25427230 http://dx.doi.org/10.1097/MNH.0000000000000088 Text en © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle CIRCULATION AND HEMODYNAMICS: Edited by Matthew R. Weir and Roland C. Blantz
Fan, Fan
Muroya, Yoshikazu
Roman, Richard J.
Cytochrome P450 eicosanoids in hypertension and renal disease
title Cytochrome P450 eicosanoids in hypertension and renal disease
title_full Cytochrome P450 eicosanoids in hypertension and renal disease
title_fullStr Cytochrome P450 eicosanoids in hypertension and renal disease
title_full_unstemmed Cytochrome P450 eicosanoids in hypertension and renal disease
title_short Cytochrome P450 eicosanoids in hypertension and renal disease
title_sort cytochrome p450 eicosanoids in hypertension and renal disease
topic CIRCULATION AND HEMODYNAMICS: Edited by Matthew R. Weir and Roland C. Blantz
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260681/
https://www.ncbi.nlm.nih.gov/pubmed/25427230
http://dx.doi.org/10.1097/MNH.0000000000000088
work_keys_str_mv AT fanfan cytochromep450eicosanoidsinhypertensionandrenaldisease
AT muroyayoshikazu cytochromep450eicosanoidsinhypertensionandrenaldisease
AT romanrichardj cytochromep450eicosanoidsinhypertensionandrenaldisease